› 3ma3

X-ray diffraction
2.3Å resolution

Crystal structure of human proto-oncogene serine threonine kinase (PIM1) in complex with a consensus peptide and a naphtho-difuran ligand

Released:
DOI: 10.2210/pdb3ma3/pdb
PDB entry 3ma3 coloured by chain, front view.
PDB entry 3ma3 coloured by chain, side view.
PDB entry 3ma3 coloured by chain, top view.
Source organism: Homo sapiens
Primary publication:
New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights.
López-Ramos M, Prudent R, Moucadel V, Sautel CF, Barette C, Lafanechère L, Mouawad L, Grierson D, Schmidt F, Florent JC, Filippakopoulos P, Bullock AN, Knapp S, Reiser JB, Cochet C
FASEB J 24 3171-85 (2010)
PMID: 20400536

Function and Biology Details

Reaction catalysed: 
ATP + a protein = ADP + a phosphoprotein
Biochemical function:
Biological process:
Cellular component:
Sequence domains:

Structure analysis Details

Assembly composition:
hetero dimer (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-145761 (preferred)
Entry contents:
2 distinct polypeptide molecules
Macromolecules (2 distinct):
Serine/threonine-protein kinase pim-1 Chain: A
Molecule details ›
Chain: A
Length: 313 amino acids
Theoretical weight: 35.67 KDa
Source organism: Homo sapiens
Expression system: Escherichia coli BL21(DE3)
UniProt:
  • Canonical: P11309 (Residues: 2-312; Coverage: 99%)
Gene name: PIM1
Sequence domains: Protein kinase domain
Structure domains:
Pimtide Chain: B
Molecule details ›
Chain: B
Length: 7 amino acids
Theoretical weight: 941 Da
Source organism: Homo sapiens
Expression system: Not provided

Ligands and Environments

1 bound ligand:
Ligand 01I 1 x 01I
1 modified residue:
Ligand SEP 1 x SEP

Experiments and Validation Details

Entry percentile scores
X-ray source: RIGAKU FR-E SUPERBRIGHT
Spacegroup: P65
Unit cell:
a: 97.707Å b: 97.707Å c: 80.581Å
α: 90° β: 90° γ: 120°
R-values:
R R work R free
0.172 0.169 0.233
Expression systems:
  • Escherichia coli BL21(DE3)
  • Not provided

Quick links

Citations

6 review citations

PIM1 kinase as a target for cancer therapy.
Merkel et al. (2012)
5 more

4 mentions without citation

Identification of the first inhibitor of the GBP1:PIM1 interaction. Implications for the development of a new class of anticancer agents against paclitaxel resistant cancer cells.
Andreoli et al. (2014)
3 more